REDHILL BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.46 USD | +0.63% |
|
+1.72% | -68.49% |
Presenter SpeechRebecca Johnson;UBS;Investment Banking Analyst (Analysts)Good morning, everyon...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelersâ diarrhea. RedHillâs clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Sector
Pharmaceuticals
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -68.49% | 14.66M | |
| +0.10% | 91.42B | |
| +2.76% | 41.08B | |
| -9.06% | 34.26B | |
| +54.31% | 25.27B | |
| -16.61% | 15.27B | |
| -9.14% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +5.24% | 9.16B |
- Stock Market
- Equities
- RDHL Stock
- News RedHill Biopharma Ltd.
- Transcript : RedHill Biopharma Ltd. Presents at UBS Virtual Global Healthcare Conference, May-18-2020 07